Drugs / SB16
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04664959 | Nov 2020 → Jun 2022 | postmenopausal osteoporosis | Samsung Bioepis Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB16 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04664959 ↗ |
| Route | Subcutaneous | “Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months.” NCT04664959 ↗ |